In Wednesday’s Wall Street session, Royalty Pharma plc (NASDAQ:RPRX) shares traded at $31.56, down -6.52% from the previous session.
RPRX stock price is now -2.50% away from the 50-day moving average and 11.11% away from the 200-day moving average. The market capitalization of the company currently stands at $18.19B.
With the price target maintained at $28, UBS recently Downgraded its rating from Buy to Neutral for Royalty Pharma plc (NASDAQ: RPRX). , while ‘Scotiabank’ rates the stock as ‘Sector Outperform’
A total of 22.85% of the company’s stock is owned by insiders.
During the past 12 months, Royalty Pharma plc has had a low of $24.05 and a high of $34.20. As of last week, the company has a debt-to-equity ratio of 1.10, a current ratio of 1.44, and a quick ratio of 1.44. According to the stock market information, the enterprise value for the company is $23696719872, which is based on a 16.46 price-to-earnings ratio, a 1.28 price-to-earnings-growth ratio, and a beta of 0.46. The fifty day moving average price for RPRX is $32.3394 and a two-hundred day moving average price translates $28.3829 for the stock.
The latest earnings results from Royalty Pharma plc (NASDAQ: RPRX) was released for 2024-12-31. The net profit margin was 37.93% and return on equity was 12.75% for RPRX. The company reported revenue of $593.64 million for the quarter, compared to $596.07 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -0.41 percent.
